PT - Artigos publicados em revistas não indexadas na Medline
Permanent URI for this collection
Browse
Browsing PT - Artigos publicados em revistas não indexadas na Medline by Author "Fernandes, I."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Do you know this syndrome?Publication . Rosmaninho, A.; Pinto-Almeida, T.; Fernandes, I.; Machado, S.; Selores, M.Abstract Lipomas are among the most common tumors seen in the soft body parts and usually are solitary lesions. The authors report a case of a male patient that presented for evaluation of multiple subcutaneous nodules that caused important functional and cosmetic impairment. The diagnosis of familial multiple lipomatosis was made. Physicians should be able to recognize and characterize this rare disease.
- Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary SyndromePublication . Fernandes, I.; Torres, T.; Selores, M.; Alves, R.; Lima, M.Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in relief of refractory pruritus in patients with SS. Material and methods: A prospective study which included four patients with SS, in whom pruritus is the main symptom, was performed. Our purpose was to assess efficacy of Aprepitant for treatment of refractory pruritus, secondary to SS. Patients were treated with Aprepitant 80 mg/d during 10 days and then the dosage was reduced to alternate days. The length of treatment ranged between 4 and 23 weeks. Improvement was assessed by the Dermatology Life Quality Index (DLQI) questionnaire, which ranges from 0 to 30, with high scores indicating worse outcome and by Visual Analogue Scale (VAS) which varies from 0 to 10, with higher scores meaning severe pruritus. Results: Prior to treatment, subjects had severe pruritus with mean DLQI score of 21.5 (SD ± 2.4) and mean VAS score of 9.0 (SD ± 0.8). At the end of the treatment, a statistically significant reduction in both indexes (p<0.05) was evident. In all patients, an improvement of pruritus was rapidly observed after the first week of therapy. No side effects were reported. Conclusion: The study confirms the effectiveness and safety of Aprepitant as an antipruritic agent in patients with refractory pruritus secondary to SS.
- Rituximab no tratamento de pênfigo vulgar refractárioPublication . Fernandes, I.; Sanches, M.; Velho, G.; Selores, M.O pênfigo vulgar é uma doença bolhosa auto-imune rara, que atinge a pele e as mucosas. Geralmente tem um curso clínico severo, sendo necessário o recurso a terapêutica prolongada com corticóides sistémicos e outros fármacos imunossupressores, que podem conduzir a efeitos adversos graves. O rituximab é um anticorpo monoclo- nal quimérico dirigido ao antigénio CD20, expresso pelos linfócitos B. Recentemente, têm surgido alguns estudos que documentam o seu sucesso terapêutico no tratamento de pênfigo refractário. Os autores descrevem dois casos clínicos de pênfigo vulgar refractários às terapêuticas convencionais, que foram tratados com rituximab, tendo atin- gido a remissão completa da doença. A experiência bem sucedida em relação a estes dois casos clínicos reforça que o rituximab constitui uma opção valiosa e segura na abordagem terapêutica do pênfigo vulgar severo e refractário.